FR 901537
Latest Information Update: 30 May 2001
Price :
$50 *
At a glance
- Originator Fujisawa
- Class Cytostatic antibiotics
- Mechanism of Action Aromatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 23 Jun 1998 Commercial data has been reviewed by Fujisawa
- 05 Nov 1997 No-Development-Reported for Breast cancer in Japan (Unknown route)